Retinal Biologics Market - 2025-2033
Description
Retinal Biologics Market: Industry Outlook
Retinal Biologics Market reached US$ 24.16 Billion in 2024 and is expected to reach US$ 40.46 Billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.
The global retinal biologics market is expected to experience significant growth over the next decade due to the increasing prevalence of retinal disorders like AMD, DR, and RVO. Retinal biologics, particularly anti-VEGF therapies, offer targeted treatments for vision loss.
North America leads the market due to high disease prevalence, robust healthcare infrastructure, and early adoption of innovative treatments. Emerging markets in Asia-Pacific and Latin America are expected to experience rapid growth due to improved healthcare access and rising awareness.
Retinal Biologics Market Dynamics: Drivers & Restraints
Driver: Rising prevalence of retinal disorders
The retinal biologics market is driven by the rising incidence of retinal diseases, particularly among the aging population. Age-related macular degeneration and diabetic retinopathy are leading causes of blindness globally. For instance, according to the World Health Organization, estimating a double-digit increase in people aged 60 and older by 2050, the demand for effective treatments is expected to surge. Biologics offer a highly effective method for managing these chronic eye conditions, preserving vision, and improving patient quality of life.
Moreover, AMD is the leading cause of vision loss and blindness in the older US population, with a projected global number of 288 million by 2050. It affects one in eight people 60 years or older in developed countries and is the most common cause of irreversible blindness in this age group. In the US, the estimated number of AMD patients is expected to double from 9 million to 18 million by 2050 due to longer life expectancy. Hence, a rise in the prevalence of retinal biologics is important, which directly helps the market for lucrative growth during the forecast period.
Restraint: Limited patient compliance due to invasive treatment methods
The retinal biologics market faces challenges due to limited patient compliance, due to the invasive nature of intravitreal injections. These treatments often require frequent injections into the eye, leading to discomfort, anxiety, and fear. Repeated injections also carry a small risk of complications like endophthalmitis, retinal detachment, or increased intraocular pressure. These factors discourage long-term adherence, reducing treatment efficacy and limiting market growth despite the availability of effective biologic solutions.
Retinal Biologics Market Segment Analysis
The global retinal biologics market is segmented based on drug class, indication, route of administration, distribution channel, and region.
Drug Class:
The anti-VEGF drugs segment of the drug class is expected to hold 41.1% of the retinal biologics market
Anti-VEGF drugs are biologic agents designed to inhibit the activity of VEGF, a protein that promotes abnormal blood vessel growth in the eye, leading to vision impairment or blindness. Common anti-VEGF agents include ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin, off-label), and brolucizumab (Beovu). These therapies work by blocking VEGF's interaction with its receptors, halting disease progression, and improving visual outcomes.
The anti-VEGF drug segment is a significant revenue generator in the retinal biologics market due to its high clinical efficacy and safety profile in treating prevalent retinal diseases like wet AMD and DME. The segment benefits from a growing patient population due to aging demographics and rising diabetes rates. Continuous innovation, such as longer-acting formulations and port delivery systems, enhances patient convenience and compliance.
Increased awareness, growing ophthalmology infrastructure, and expanded reimbursement coverage in developed markets contribute to the rapid adoption of anti-VEGF treatments, making it the most dominant and fastest-growing segment in the global retinal biologics market.
Retinal Biologics Market Geographical Analysis
North America dominated the global retinal biologics market with the highest share of 40.3% in 2024
North America dominates the global retinal biologics market due to its established healthcare infrastructure, early adoption of advanced therapies, and high prevalence of age-related macular degeneration and diabetic retinopathy.
The region has major market players, strong research and development capabilities, and patient awareness. Favorable reimbursement policies and wide insurance coverage make biologics more accessible. The U.S. has numerous ophthalmologists and specialty clinics, ensuring timely diagnosis and treatment. Ongoing clinical trials and regulatory approval further boost market growth.
For instance, in April 2025, The US FDA has accepted the resubmission of Outlook Therapeutics' Biologics License Application for ONS-5010, a treatment for wet age-related macular degeneration. The FDA determined the resubmission was a Class 2 review, resulting in a 6-month review period. A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 was set by the FDA. If approved, the drug will be branded as LYTENAVA in the US.
Asia-Pacific region in the global retinal biologics market is expected to grow with the highest CAGR of 17.5% in the forecast period of 2025 to 2033
The Asia Pacific region is the fastest-growing market for retinal biologics, driven by rising diabetes incidence, urbanization, aging populations, and increasing healthcare spending. Improved access to diagnostic technologies and expanding healthcare infrastructure are facilitating earlier detection and treatment of retinal disorders. Government initiatives and global pharmaceutical companies' investments are accelerating the adoption of biologics. As awareness and affordability improve, Asia Pacific is expected to play a pivotal role in the global retinal biologics market's future growth.
For instance, in July 2024, Boan Biotech received approval from China's National Medical Products Administration's CDE for its Aflibercept Intravitreous Injection (BA9101), a biosimilar to EYLEA, for treating neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in adults.
Retinal Biologics Market Key Players
The major global players in the retinal biologics market include Bayer AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Oxurion NV, Chengdu Kanghong Biotech, Novartis International AG, Intas Pharmaceuticals Ltd, and Samsung Bioepis, among others.
Industry Key Developments
• In April 2025, Biocon Biologics Ltd signed a settlement and license agreement with Regeneron, allowing the commercialization of Yesafili (aflibercept-jbvf), an interchangeable biosimilar of its reference product EYLEA (aflibercept). YESAFILI, a vascular endothelial growth factor inhibitor, is used to treat various ophthalmology conditions and is a biosimilar of EYLEA.
Retinal Biologics Market reached US$ 24.16 Billion in 2024 and is expected to reach US$ 40.46 Billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.
The global retinal biologics market is expected to experience significant growth over the next decade due to the increasing prevalence of retinal disorders like AMD, DR, and RVO. Retinal biologics, particularly anti-VEGF therapies, offer targeted treatments for vision loss.
North America leads the market due to high disease prevalence, robust healthcare infrastructure, and early adoption of innovative treatments. Emerging markets in Asia-Pacific and Latin America are expected to experience rapid growth due to improved healthcare access and rising awareness.
Retinal Biologics Market Dynamics: Drivers & Restraints
Driver: Rising prevalence of retinal disorders
The retinal biologics market is driven by the rising incidence of retinal diseases, particularly among the aging population. Age-related macular degeneration and diabetic retinopathy are leading causes of blindness globally. For instance, according to the World Health Organization, estimating a double-digit increase in people aged 60 and older by 2050, the demand for effective treatments is expected to surge. Biologics offer a highly effective method for managing these chronic eye conditions, preserving vision, and improving patient quality of life.
Moreover, AMD is the leading cause of vision loss and blindness in the older US population, with a projected global number of 288 million by 2050. It affects one in eight people 60 years or older in developed countries and is the most common cause of irreversible blindness in this age group. In the US, the estimated number of AMD patients is expected to double from 9 million to 18 million by 2050 due to longer life expectancy. Hence, a rise in the prevalence of retinal biologics is important, which directly helps the market for lucrative growth during the forecast period.
Restraint: Limited patient compliance due to invasive treatment methods
The retinal biologics market faces challenges due to limited patient compliance, due to the invasive nature of intravitreal injections. These treatments often require frequent injections into the eye, leading to discomfort, anxiety, and fear. Repeated injections also carry a small risk of complications like endophthalmitis, retinal detachment, or increased intraocular pressure. These factors discourage long-term adherence, reducing treatment efficacy and limiting market growth despite the availability of effective biologic solutions.
Retinal Biologics Market Segment Analysis
The global retinal biologics market is segmented based on drug class, indication, route of administration, distribution channel, and region.
Drug Class:
The anti-VEGF drugs segment of the drug class is expected to hold 41.1% of the retinal biologics market
Anti-VEGF drugs are biologic agents designed to inhibit the activity of VEGF, a protein that promotes abnormal blood vessel growth in the eye, leading to vision impairment or blindness. Common anti-VEGF agents include ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin, off-label), and brolucizumab (Beovu). These therapies work by blocking VEGF's interaction with its receptors, halting disease progression, and improving visual outcomes.
The anti-VEGF drug segment is a significant revenue generator in the retinal biologics market due to its high clinical efficacy and safety profile in treating prevalent retinal diseases like wet AMD and DME. The segment benefits from a growing patient population due to aging demographics and rising diabetes rates. Continuous innovation, such as longer-acting formulations and port delivery systems, enhances patient convenience and compliance.
Increased awareness, growing ophthalmology infrastructure, and expanded reimbursement coverage in developed markets contribute to the rapid adoption of anti-VEGF treatments, making it the most dominant and fastest-growing segment in the global retinal biologics market.
Retinal Biologics Market Geographical Analysis
North America dominated the global retinal biologics market with the highest share of 40.3% in 2024
North America dominates the global retinal biologics market due to its established healthcare infrastructure, early adoption of advanced therapies, and high prevalence of age-related macular degeneration and diabetic retinopathy.
The region has major market players, strong research and development capabilities, and patient awareness. Favorable reimbursement policies and wide insurance coverage make biologics more accessible. The U.S. has numerous ophthalmologists and specialty clinics, ensuring timely diagnosis and treatment. Ongoing clinical trials and regulatory approval further boost market growth.
For instance, in April 2025, The US FDA has accepted the resubmission of Outlook Therapeutics' Biologics License Application for ONS-5010, a treatment for wet age-related macular degeneration. The FDA determined the resubmission was a Class 2 review, resulting in a 6-month review period. A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 was set by the FDA. If approved, the drug will be branded as LYTENAVA in the US.
Asia-Pacific region in the global retinal biologics market is expected to grow with the highest CAGR of 17.5% in the forecast period of 2025 to 2033
The Asia Pacific region is the fastest-growing market for retinal biologics, driven by rising diabetes incidence, urbanization, aging populations, and increasing healthcare spending. Improved access to diagnostic technologies and expanding healthcare infrastructure are facilitating earlier detection and treatment of retinal disorders. Government initiatives and global pharmaceutical companies' investments are accelerating the adoption of biologics. As awareness and affordability improve, Asia Pacific is expected to play a pivotal role in the global retinal biologics market's future growth.
For instance, in July 2024, Boan Biotech received approval from China's National Medical Products Administration's CDE for its Aflibercept Intravitreous Injection (BA9101), a biosimilar to EYLEA, for treating neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in adults.
Retinal Biologics Market Key Players
The major global players in the retinal biologics market include Bayer AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Oxurion NV, Chengdu Kanghong Biotech, Novartis International AG, Intas Pharmaceuticals Ltd, and Samsung Bioepis, among others.
Industry Key Developments
• In April 2025, Biocon Biologics Ltd signed a settlement and license agreement with Regeneron, allowing the commercialization of Yesafili (aflibercept-jbvf), an interchangeable biosimilar of its reference product EYLEA (aflibercept). YESAFILI, a vascular endothelial growth factor inhibitor, is used to treat various ophthalmology conditions and is a biosimilar of EYLEA.
Table of Contents
180 Pages
- 1. Market Introduction and Scope
- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope
- 2. Executive Insights and Key Takeaways
- 3. Market Highlights and Strategic Takeaways
- 3.1. Key Trends and Future Projections
- 4. Snippet by Drug Class
- 4.1. Snippet by Indication
- 4.2. Snippet by Route of Administration
- 4.3. Snippet by Distribution Channel
- 4.4. Snippet by Region
- 5. Dynamics
- 5.1. Impacting Factors
- 5.1.1. Drivers
- 5.1.1.1. Rising Prevalence of Retinal Disorders
- 5.1.1.2. Rise of Novel Techniques in Research and Development
- 5.1.1.3. XX
- 5.1.2. Restraints
- 5.1.2.1. Limited Patient Compliance due to Invasive Treatment Methods
- 5.1.2.2. Regulatory Challenges
- 5.1.2.3. XX
- 5.1.3. Opportunity
- 5.1.3.1. Emerging Biologic Therapies
- 5.1.3.2. XX
- 5.1.4. Impact Analysis
- 6. Strategic Insights and Industry Outlook
- 6.1. Market Leaders and Pioneers
- 6.1.1. Emerging Pioneers and Prominent Players
- 6.1.2. Established leaders with largest largest-selling Brand
- 6.1.3. Market leaders with established products & Services
- 6.2. CXO Perspectives
- 6.3. Latest Developments and Breakthroughs
- 6.4. Case Studies/Ongoing Research
- 6.5. Regulatory and Reimbursement Landscape
- 6.5.1. North America
- 6.5.2. Europe
- 6.5.3. Asia Pacific
- 6.5.4. South America
- 6.5.5. Middle East & Africa
- 6.6. Porter’s Five Force Analysis
- 6.7. Supply Chain Analysis
- 6.8. Patent Analysis
- 6.9. SWOT Analysis
- 6.10. Unmet Needs and Gaps
- 6.11. Recommended Strategies for Market Entry and Expansion
- 6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 6.13. Pricing Analysis and Price Dynamics
- 6.14. Key Opinion Leaders
- 7. Global Retinal Biologics Market, By Drug Class
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Anti-VEGF Drugs*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Aflibercept
- 7.2.4. Ranibizumab
- 7.2.5. Bevacizumab
- 7.2.6. Brolucizumab
- 7.3. Corticosteroids
- 7.3.1. Dexamethasone
- 7.3.2. Fluocinolone Acetonide
- 7.4. Others
- 8. Global Retinal Biologics Market, By Indication
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 8.1.2. Market Attractiveness Index, By Indication
- 8.2. Age-related Macular Degeneration (AMD)*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Diabetic Retinopathy (DR)
- 8.4. Retinal Vein Occlusion (RVO)
- 8.5. Uveitis
- 8.6. Others
- 9. Global Retinal Biologics Market, By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Intravitreal*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Systemic
- 10. Global Retinal Biologics Market, By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies
- 11. Retinal Biologics Market Regional Market Analysis and Growth Opportunities
- 12. Introduction
- 12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.1. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.2.7.1. U.S.
- 12.2.7.2. Canada
- 12.2.7.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.3.7.1. Germany
- 12.3.7.2. U.K.
- 12.3.7.3. France
- 12.3.7.4. Spain
- 12.3.7.5. Italy
- 12.3.7.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.7.1. Brazil
- 12.4.7.2. Argentina
- 12.4.7.3. Rest of South America
- 12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.5.7.1. China
- 12.5.7.2. India
- 12.5.7.3. Japan
- 12.5.7.4. South Korea
- 12.5.7.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13. Competitive Landscape and Market Positioning
- 14. Competitive Overview and Key Market Players
- 14.1. Market Share Analysis and Positioning Matrix
- 14.2. Strategic Partnerships, Mergers & Acquisitions
- 14.3. Key Developments in Drug Class Portfolios and Innovations
- 14.4. Company Benchmarking
- 15. Company Profiles
- 15.1. Bayer AG*
- 15.1.1. Company Overview
- 15.1.2. Drug Class Portfolio
- 15.1.2.1. Drug Class Description
- 15.1.2.2. Drug Class Key Performance Indicators (KPIs)
- 15.1.2.3. Historic and Forecasted Drug Class Sales
- 15.1.2.4. Drug Class Sales Volume
- 16. Financial Overview
- 16.1. Company Revenue
- 16.1.1. Geographical Revenue Shares
- 16.1.1.1. Revenue Forecasts
- 16.1.2. Key Developments
- 16.1.2.1. Mergers & Acquisitions
- 16.1.2.2. Key Drug Class Development Activities
- 16.1.2.3. Regulatory Approvals, etc.
- 16.1.3. SWOT Analysis
- 16.2. F. Hoffmann-La Roche Ltd
- 16.3. Regeneron Pharmaceuticals Inc
- 16.4. Oxurion NV
- 16.5. Chengdu Kanghong Biotech
- 16.6. Novartis International AG
- 16.7. Intas Pharmaceuticals Ltd
- 16.8. Samsung Bioepis (*LIST NOT EXHAUSTIVE)
- 17. Assumptions and Research Methodology
- 17.1. Data Collection Methods
- 17.2. Data Triangulation
- 17.3. Forecasting Techniques
- 17.4. Data Verification and Validation
- 18. Appendix
- 18.1. About Us and Services
- 18.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
